Oruka Therapeutics, Inc.
ORKA
$76.68-1.51 (-1.93%)
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
StreetsValue research for Oruka Therapeutics, Inc. (ORKA)
Members get the full report for Oruka Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.